Dermatology Products · LP-098
Fusidic acid Cream
Generic medicine development record. Review the proposed presentation and the professional reference information below.
Development record
- Portfolio reference
- LP-098Dermatology Products
- Generic identity
- Fusidic acidCream
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Ingredient reference
Record identity and reference background.
- Portfolio reference
- LP-098
- Generic ingredient
- Fusidic acid
- Dosage form
- Cream
- Proposed strength
- 2%
- Proposed pack
- Tube 15 g
- Portfolio category
- Dermatology Products
About Fusidic acid
Fusidic acid is an antibiotic ingredient used in certain topical medicines for susceptible bacterial skin infections. A cream is intended to deliver the antibiotic locally; it is distinct from eye preparations and systemic fusidic acid products. Its place in care depends on the suspected organism and local antimicrobial guidance. A red or inflamed skin lesion does not alone establish a bacterial infection or justify an antibiotic.
How to read this profile
Scientific information relates to the ingredient and dosage-form context. It is not approved Luang Pharma labelling, a clinical recommendation, or evidence of equivalence to a referenced product. Multiple strengths or presentations represent separate proposed variants and must not be treated as interchangeable.
02 · Professional background
Scientific & clinical reference
Read the clinical context, selected safety considerations and presentation-specific information below.
Clinical context and therapeutic role
Clinical assessment distinguishes a localized superficial infection from a spreading infection, abscess, dermatitis or fungal disease. Impetigo is one setting discussed by NHS medicine information, but the need for a topical or systemic approach depends on severity and local recommendations. Repeated or prolonged unsupervised antibiotic use can promote resistance. Failure to improve should prompt reassessment and, where appropriate, microbiological investigation rather than automatic extension of treatment.
Important safety considerations
Topical fusidic acid can cause irritation or allergic skin reactions. Marked swelling, hives or breathing difficulty require urgent assessment. Avoid application to eyes unless the product is specifically an ophthalmic formulation. The risk profile of a cream differs from oral fusidic acid, so warnings and interaction lists must be matched to the route. Excipients can also cause sensitivity and should be checked in the product leaflet.
These are selected considerations, not a complete list. Use the current instructions or approved label for the exact authorised product and seek appropriate professional advice.
Presentation, handling and storage
This record is for fusidic acid cream alone. It should not be described as a steroid-antibiotic combination, eye drop or oral antibiotic. The base composition, application instructions and permitted patient groups must come from the approved product information.
Keep the medicine in the labelled original pack with its leaflet. Check the expiry date and pack integrity before dispensing. The authorized label must determine storage temperature, protection from moisture or light, and disposal; no shelf life or in-use period can be established from a catalogue entry.
Final composition, instructions, shelf life and storage conditions are not established by this portfolio entry. They must come from the controlled documentation for the specific product.
Points for professional review
Review diagnosis, lesion extent, susceptibility considerations, allergy history and antimicrobial stewardship. Confirm that the specific formulation is authorized for the intended clinical use.
03 · Product enquiry
Documentation & regulatory status
Evidence status
What is established — and what remains open
This record has received an editorial evidence-layer review. The review separates catalogue facts from unresolved product-specific fields and external context; it is not medical, regulatory or market-authorisation approval.
Layer 01
Controlled catalogue facts
- Generic ingredient
- Fusidic acid
- Dosage form / presentation
- Cream
- Catalogue strength
- 2%
- Catalogue pack
- Tube 15 g
- Portfolio category
- Dermatology Products
Layer 02
Unresolved product-specific fields
- Exact vehicle/excipient system, intended application site and formulation-specific instructions require controlled product documentation.
- Approved indication, patient eligibility and dosing are not established by this portfolio record.
- Registration, manufacturing/site status, supply availability, storage conditions and shelf life remain product- and market-specific evidence items.
Layer 03
Attributed external context
- NHS: fusidic acidpublic health service medicine information
- NHS: fusidic acid adverse effectsgovernment or public health guidance
These references provide scientific or regulatory context only. They are not Luang Pharma product labelling, registration, manufacturing evidence, equivalence evidence or confirmation of supply.
Layer 04
Documents required to close the record
- Controlled product master/specification confirming the exact ingredient identity, dosage form, strength variant and pack mapping.
- Destination-market authorisation or other lawful supply-route evidence plus the approved label/leaflet/IFU, where applicable.
- Product-specific composition/excipient, storage, shelf-life and pack-control documentation.
- Manufacturing-site and supply-status evidence before any public claim of installed capability, registration, availability or equivalence.
For LP-098, identify the destination country, intended professional use, proposed presentation and the role of your organisation. The appropriate supply route and available documentation must be confirmed for that case.
- Confirm the legal entity, manufacturing site and authorised scope for the proposed supply chain.
- Confirm product registration or another lawful route, approved labelling and the applicable destination requirements.
- Request relevant product information, specifications and supporting evidence through the company contact.
- Confirm storage, transport, traceability, complaints and safety-reporting responsibilities before any agreement.
The public catalogue extends beyond the initial planned facility modules. A listing does not mean that the dosage form is installed, qualified or licensed at Boten.
04 · External sources
Sources and further reading
External sources are provided for reference. Their authors do not endorse Luang Pharma, and another product’s authorisation does not transfer to this portfolio record. Source availability and wording can change.
Professional enquiries
Request product-specific evidence for LP-098.
State the exact presentation, organisation, destination and evidence needed. This public record is not an offer of supply.